X0306 4 2021-01-19 0 0001674416 CRISPR Therapeutics AG CRSP 0001708172 KASINGER JAMES R. C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 0 1 0 0 General Counsel and Secretary Common Shares 2021-01-19 4 M 0 27500 51.49 A 49931 D Common Shares 2021-01-19 4 S 0 6785 203.58 D 43146 D Common Shares 2021-01-19 4 S 0 7818 204.40 D 35328 D Common Shares 2021-01-19 4 S 0 8997 205.60 D 26331 D Common Shares 2021-01-19 4 S 0 1800 206.05 D 24531 D Common Shares 2021-01-19 4 S 0 2100 207.61 D 22431 D Stock Option (right to buy) 51.49 2021-01-19 4 M 0 27500 0.00 D 2028-03-07 Common Shares 27500 12500 D Includes 16 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.00 to $203.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.00 to $204.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.00 to $205.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.00 to $206.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.39 to $208.1050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option was granted on March 7, 2018 with respect to 40,000 Common Shares and vests in 48 equal monthly installments. /s/ Michael Esposito, attorney-in-fact 2021-01-20